

FIVE-WEEK NERVE GROWTH FACTOR TREATMENT IS SAFE FOR BRAIN REPAIR



Nina Colitti*, Franck Desmoulin*, Wafae Labriji*, Alice Le Friec*, Lorenne Robert*, Amandine Michaux‡, Fabrice Conchou‡, Carla Cirillo*, and Isabelle Loubinoux*, *Toulouse NeuroImaging Center (ToNIC), Inserm, University of Toulouse, France ; ‡National Veterinary School of Toulouse, University of Toulouse, Toulouse, France

Introduction

- > Stroke is the leading cause of acquired severe motor disability in adults.
- > The brain has limited ability to reconstruct itself by generating new neurons from stem cells.
- \succ New neurons survival is too low (0.2%) to induce recover.
- > Low survival is also due to the lack of growth factors.



This study focuses on Nerve Growth Factor (NGF) : neuroprotective/anti-inflammatory/stimulating neurogenesis effects. The intranasal (IN) pathway was chosen as delivery route.



- Limb-use asymmetry test
- week Lesion volume and Reconstructed Tissue (RT) identification were evaluated by:
 - MRI T2 weighted images
 - Nissl staining coloration (RT calculated on Case viewer software ; % of RT is normalized to the size of the lesion)
 - Immunostaining: OGFAP: glial scar/astrocytes Olba1: microglia OPDGFRb: vessels/pericytes ODoublecortin: neurons progenitors • NeuN: mature neurons • beta 3 tubulin: immature neurons

Results

3

•••

- MRI T2 weighted might be a reliable biomarker for reconstructed tissue evaluation
- Migration pathways coming from the anterior part of the ventricle until the edge of the lesion •

Treatment: IN administration of NGF (n=9) Control: IN administration of Physiological Serum (PS; n=9)

- Long-term NGF treatment promotes tissue reconstruction and remodeling •
- NGF induces a significant increase in the percentage of mature neurons in the reconstructed tissue compared to PS (*p=0.0043*)
- Five-week NGF treatment is safe; however ten-week treatment retarded motor recovery (p=0.01) •••

Identification and quantification of reconstructed tissue

Immunofluorescence of reconstructed tissue brain section







- First study with long-term NGF treatment
- Reconstructed tissue characterized for the first time at 3 month post injury
- The nose-to-brain pathway is a valid strategy for repeated and non-invasive administrations : Hope for chronic stroke treatment

Donnan GA et al., Stroke, 2008 ; Arvidsson A et al., Nat Med, 2002 ; Khelif Y et al., Theranostics, 2018; Zhu W et al., Drug Deliv, 2011; R. G. THORNE et al., Neuroscience, 2004; Davoust C et al., Stem Cells Res Ther, 2017

- Nina Colitti - iDREAM team Toulouse NeuroImaging Center - nina.colitti@inserm.fr -

Conclusion

In this preclinical study, we show that five-week intranasal NGF treatment is safe and promotes tissue regeneration with a significantly higher proportion of neurons observed twelve weeks after brain injury.